EUCTR2022-000258-27-DE招募中1 期
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults - Safety and immunogenicity of V116 in pneumococcal vaccine-naïve adults
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 2,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. The participant may have underlying chronic conditions if they are assessed to be stable as per the investigator’s judgment.
- •2. Is male or female, =18 years of age, at the time of informed consent.
- •3. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Not a WOCBP
- •A WOCBP and:
- •- Uses an acceptable contraceptive method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 6 weeks after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •- Has a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
- •- Medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a woman with an early undetected pregnancy.
- •4. The participant (or legally acceptable representative) has provided documented informed consent for the study. The participant may also provide documented informed consent for FBR and/or assay development sample collection. However, the participant may be enrolled in the study without providing consent for FBR or assay development sample collection.
- •5. The participant has the ability to complete eVRC data collection without assistance based on judgment of the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1450
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1150
排除标准
- •1. Has a history of IPD (positive blood culture, positive cerebrospinal fluid culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease within 3 years of Visit 1 (Day 1).
- •2. Has a known hypersensitivity to any component of V116 or PCV20, including diphtheria toxoid.
- •3. Has a known or suspected impairment of immunological function including, but not limited to, a history of congenital or acquired immunodeficiency, documented HIV infection, functional or anatomic asplenia, or history of autoimmune disease.
- •4. Has a coagulation disorder contraindicating IM vaccination.
- •5. *Had a recent febrile illness (defined as oral or tympanic temperature =100.4°F [=38.0°C] or axillary or temporal temperature =99.4°F [=37.4°C]) or received antibiotic therapy for any acute illness occurring <72 hours before receipt of study vaccine.
- •6. Has a known malignancy that is progressing or has required active treatment <3 years before enrollment.
- •7. Received prior administration of any pneumococcal vaccine or is expected to receive any pneumococcal vaccine during the study outside the protocol. Exception: participants with childhood pneumococcal vaccination prior to the age of 5 will be permitted.
- •8. *Received systemic corticosteroids (prednisone equivalent of =20 mg/day) for =14 consecutive days and has not completed intervention =14 days before receipt of study vaccine.
- •9. Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
- •10. *Received any nonlive vaccine =14 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine =30 days after receipt of study vaccine. Exception: inactivated influenza vaccine and SARS-CoV-2 mRNA or SARS-CoV-2 protein subunit vaccine may be administered but must be given =7 days before or =15 days after receipt of study vaccine.
- •11. *Received any live virus vaccine =30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine =30 days after receipt of study vaccine.
- •12. Received a blood transfusion or blood products, including immunoglobulin =6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete. Autologous blood transfusions are not considered an exclusion criterion.
- •13. Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.
- •14. In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
- •15. Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant’s participation for the full duration of the study.
- •16. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
- •For items with an asterisk (*), if the participant meets these exclusion criteria, Visit 1 may be rescheduled for a time whe
研究者
相似试验
进行中（未招募）
1 期
Safety and Immunogenicity of V114 in Recipients of Allo-HSCTPneumococcal diseaseMedDRA version: 20.0Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-000066-11-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
A clinical study of the V116 vaccine for adults who have an increased risk for invasive pneumococcal diseasePneumococcal infectionMedDRA version: 20.0Level: LLTClassification code: 10035644Term: Pneumococcal infection NOS Class: 10021881CTIS2022-502791-22-01Merck Sharp & Dohme LLC500
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM) - Safety and Immunogenicity of V114 in Recipients of Allo-HSCTPneumococcal diseaseMedDRA version: 20.0Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-000066-11-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
Safety and immunogenicity of V116 in pneumococcal vaccine-naïve adultsEUCTR2022-000258-27-SEMerck Sharp & Dohme LLC2,600
进行中（未招募）
1 期
Safety and Immunogenicity of V114 in Recipients of Allo-HSCTPneumococcal diseaseMedDRA version: 20.0Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-000066-11-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300